Back to top

Image: Bigstock

Masimo (MASI) Expands Partnership with Texas-Based Drager

Read MoreHide Full Article

Masimo Corporation MASI recently announced the expansion of its partnership with Dräger, where the latter will integrate Masimo’s technologies to help clinicians assess brain function, oxygenation and ventilation status.

For investors’ notice, Dräger is a leading company in the fields of medical and safety technology. The company had partnered with Masimo way back in 1999.

Earlier, Dräger had integrated Masimo’s noninvasive, continuous rainbow SET technologies, including total hemoglobin in its patient monitors.

More on the Expansion

Per management at Masimo, Dräger will add Masimo SedLine Brain Function Monitoring, O3 Regional Oximetry, and NomoLine Capnography measurements to its comprehensive suite of advanced measurement parameters.

Next Generation SedLine Brain Function Monitoring assists clinicians in monitoring the state of the brain under anesthesia, while O3 Regional Oximetry helps clinicians monitor cerebral oxygenation in patients. The NomoLine platform is designed for low-flow applications and can be used in a variety of clinical scenarios and care settings.

Clearly, the latest development is expected to boost the demand for Masimo’s unique offerings.

Developments Galore

The company has received CE mark for neonatal use of its continuous hemoglobin monitoring technology.

In September, the company announced Pathway, a new monitoring feature for guiding neonatal resuscitation. Additionally, the company has announced that the delta cerebral hemoglobin, delta oxyhemoglobin and delta deoxyhemoglobin indices are available on its O3 Regional Oximetry offering.


Price Performance

Reflective of these, the Zacks Rank #3 (Hold) company has rallied 55.3% compared with the industry’s 25.7% rise in a year’s time.

Key Picks

A few better-ranked stocks from the broader medical space are CONMED Corp. CNMD, HealthEquity HQY and West Pharmaceutical Services (WST - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Conmed has a long-term earnings growth rate of 17%.

HealthEquity has a long-term earnings growth rate of 25%.

West Pharmaceuticals has a long-term earnings growth rate of 14%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

West Pharmaceutical Services, Inc. (WST) - Free Report >>